PROTOCOL ALD-102 AN OPEN LABEL, NON-RANDOMIZED, SINGLE DOSE, MULTI-CENTER PHASE 2 3 STUDY OF THE SAFETY AND EFFICACY OF LENTI-D MODIFIED AUTOLOGOUS STEM CELLS (LENTI-D DRUG PRODUCT) FOR THE TREATMENT OF SUBJECTS WITH CHI - Adrenoleukodystrophy - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2013-12-31 13:09:44 Peroxisomal disorders Rare diseases Adrenoleukodystrophy Leukodystrophies Hematopoietic stem cell transplantation Myelin Medicine Health Biology		PROTOCOL ALD-102 AN OPEN LABEL, NON-RANDOMIZED, SINGLE DOSE, MULTI-CENTER PHASE 2/3 STUDY OF THE SAFETY AND EFFICACY OF LENTI-D MODIFIED AUTOLOGOUS STEM CELLS (LENTI-D DRUG PRODUCT) FOR THE TREATMENT OF SUBJECTS WITH CHI Add to Reading List Source URL: osp.od.nih.gov Download Document from Source Website File Size: 2,77 MB Share Document on Facebook